Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 19.4% during trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares changed hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a market cap of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20. The firm has a 50 day simple moving average of C$0.20 and a 200-day simple moving average of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Investors Need to Know About Upcoming IPOs
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What Investors Need to Know to Beat the Market
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Investing in the High PE Growth Stocks
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
